Edition:
United States

Novartis AG (NVS)

NVS on New York Consolidated

89.88USD
15 Feb 2019
Change (% chg)

$0.86 (+0.97%)
Prev Close
$89.02
Open
$89.11
Day's High
$89.99
Day's Low
$89.07
Volume
2,351,443
Avg. Vol
2,659,484
52-wk High
$92.39
52-wk Low
$72.30

Summary

Name Age Since Current Position

Joerg Reinhardt

63 2013 Independent Non-Executive Chairman of the Board

Alex Krauer

69 Honorary Chairman of the Board

Daniel Vasella

66 Honorary Chairman of the Board

Vasant Narasimhan

43 2018 Chief Executive Officer, Member of the Executive Committee

Enrico Vanni

68 2013 Independent Non-Executive Vice Chairman of the Board

Harry Kirsch

54 2013 Chief Financial Officer, Member of the Executive Committee

Steven Baert

45 2014 Chief People & Organization Officer, Member of the Executive Committee

Steffen Lang

52 2018 Global Head of Novartis Technical Operations, Member of the Executive Committee

Klaus Moosmayer

51 2018 Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee

Shannon Klinger

48 2018 Group General Counsel, Member of the Executive Committee

Bertrand Bodson

44 2018 Chief Digital Officer, Member of the Executive Committee

James Bradner

47 2016 President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee

Richard Francis

51 2014 Chief Executive Officer of Sandoz, Member of the Executive Committee

Paul Hudson

52 2016 Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee

Susanne Schaffert

52 2019 CEO Novartis Oncology, Member of the Executive Committee

John Tsai

52 2018 Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee

Robert Weltevreden

50 2018 Head of Novartis Business Services (NBS), Member of the Executive Committee

Charlotte Pamer-Wieser

2011 Corporate Secretary

Nancy Andrews

61 2015 Non-Executive Independent Director

Dimitri Azar

60 2012 Non-Executive Independent Director

Ton Buechner

54 2016 Non-Executive Independent Director

Srikant Datar

66 2003 Non-Executive Independent Director

Elizabeth Doherty

62 2016 Non-Executive Independent Director

Ann Fudge

68 2008 Non-Executive Independent Director

Charles Sawyers

60 2013 Non-Executive Independent Director

Frans van Houten

59 2017 Non-Executive Independent Director

Andreas von Planta

63 2006 Non-Executive Independent Director

William Winters

58 2013 Non-Executive Independent Director

Samir Shah

2013 Global Head Investor Relations

Biographies

Name Description

Joerg Reinhardt

Mr. Joerg Reinhardt, Ph.D., has been Independent Non-Executive Chairman of the Board of Novartis Inc. since August 1, 2013. He is also Chairman of the Research & Development Committee and Chairman of the Board of Trustees of the Novartis Foundation. Mr. Reinhardt is Chairman of the board of trustees of the Institute of Molecular and Clinical Ophthalmology Basel (IOB), Switzerland. From 2010 to mid-2013, he was Chairman of the Board of Management and the Executive Committee of Bayer HealthCare, Germany. Prior to that, he was Chief Operating Officer of Novartis from 2008 to 2010, and Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. Mr. Reinhardt is a non-executive board member of Swiss Re, Switzerland, and a member of the European Advisory Panel of Temasek, Singapore. Additionally, he was a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013, Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010, and a member of the supervisory board of MorphoSys AG in Germany from 2001 to 2004. Mr. Reinhardt graduated with a doctorate in pharmaceutical sciences from Saarland University in Germany. He joined Sandoz Pharma Ltd. in 1982 and held various positions at Sandoz and later Novartis, including Head of Development.

Alex Krauer

Dr. Alex Krauer, Ph.D., is Honorary Chairman of the Board of Novartis Inc. He was Chairman of the Board at the Company until 1999.

Daniel Vasella

Dr. Daniel L. Vasella, M.D., is Honorary Chairman of the Board of Novartis Inc. He was Chairman of the Board of Directors of Novartis from February 1, 2010 until 2013. He was Chairman of the Chairman's Committee at the Company. He resigned from his position as Chief Executive Officer (CEO) of the Company on February 1, 2010. He had served as CEO and Executive Member of the Board of Directors of Novartis AG since the merger that created Novartis AG in 1996. He was appointed Company's Chairman of the Board of Directors in 1999. Befor the Novartis AG merger, Dr. Vasella was CEO of Sandoz Pharma Ltd. and Member of the Sandoz Group Executive Committee. From 1988 to 1992, he was with Sandoz Pharmaceuticals Corporation in the United States, prior to which he held a number of medical positions in Switzerland. Dr. Vasella is Member of the Board of Directors of PepsiCo, Inc. He is also Member of the International Board of Governors of the Peres Center for Peace in Israel, the International Business Leaders Advisory Council for the Mayor of Shanghai, the Global Health Program Advisory Panel of the Bill & Melinda Gates Foundation, and is a foreign Honorary Member of the American Academy of Arts and Sciences. He is also Member of the Board of Trustees of the Carnegie Endowment for International Peace. In addition, Dr. Vasella serves as Member of several industry associations and educational institutions. Dr. Vasella graduated with a Medical Doctor (M.D.) title from Universitaet Bern in 1979. Dr. Vasella has been honored with several awards, including the Harvard Business School's Alumni Achievement Award and Appeal of Conscience Award, the AJ Congress Humanitarian Award, the Ordem Nacional do Cruzeiro do Sul (Brazil), and holds the rank of Chevalier in the Ordre national de la Legion d'honneur (France). He was also awarded an honorary doctorate by the University of Basel.

Vasant Narasimhan

Dr. Vasant (Vas) Narasimhan, M.D., has been Chief Executive Officer, Member of the Executive Committee of Novartis Inc. since February 1, 2018. He was Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee of Novartis Inc. from February 1, 2016. Dr. Narasimhan previously was Global Head of Development for Novartis Pharmaceuticals, overseeing the entire general medicines pipeline. He has also served as Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company. Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago. During and after his medical studies, he worked on a range of public health issues in developing countries. He is an elected member of the United States National Academy of Medicine and serves on the board of fellows of Harvard Medical School.

Enrico Vanni

Dr. Enrico (Henri) Vanni, Ph.D., has been Independent Non-Executive Vice Chairman of the Board at Novartis Inc. since February 22, 2013. He was Member of the Board of Directors at Novartis AG since 2011 till February 22, 2013. He is Chairman of the Compensation Committee. He is also Member of the Audit and Compliance Committee and the Governance, Nomination and Corporate Responsibilities Committee. Mr. Vanni retired as director of McKinsey & Company in 2007. He is a board member of several companies in industries from healthcare to private banking, including Advanced Oncotherapy PLC in the United Kingdom, and non-listed companies such as Lombard Odier SA, Banque Privee BCP (Suisse) SA, and Denzler & Partners SA – all based in Switzerland. He previously served on the boards of Eclosion2 in Switzerland from 2009 to 2017, of Alcon Inc. in Switzerland from 2010 to 2011, and of Actavis PLC in Ireland in 2010. Mr. Vanni holds an engineering degree in chemistry from the Federal Polytechnic School of Lausanne, Switzerland; a doctorate in chemistry from the University of Lausanne; and a Master of Business Administration from INSEAD in Fontainebleau, France. He began his career as a research engineer at the International Business Machines Corp. (IBM) in California, United States, and joined McKinsey in Zurich in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led McKinsey’s European pharmaceutical practice and served as a member of the firm’s partner review committee prior to his retirement. From 2008 to 2015, he was an independent consultant, supporting leaders of pharmaceutical and biotechnology companies on core strategic challenges facing the healthcare industry.

Harry Kirsch

Mr. Harry Kirsch has been Chief Financial Officer and Member of the Executive Committee of Novartis Inc. since May 1, 2013. Mr. Kirsch joined Novartis in 2003 and, prior to his current position, served as CFO of the Company’s Pharmaceuticals Division. Under his leadership, the division’s core operating income margin increased, in constant currencies, every quarter of 2011 and 2012 despite patent expirations. At Novartis, he also served as CFO of Pharma Europe, and as Head of Business Planning & Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G’s global pharmaceutical business. Prior to that, he held finance positions in various categories of P&G’s consumer goods business, technical operations, and Global Business Services organization. Mr. Kirsch holds a diploma degree in industrial engineering and economics from the University of Karlsruhe in Germany. From 2015 to 2018, he represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd.

Steven Baert

Mr. Steven Baert has been Chief People & Organization Officer, Member of the Executive Committee of Novartis Inc. since February 26, 2014. Mr. Baert joined Novartis in 2006 as Head of Human Resources Global Functions in Switzerland. He has held other leadership roles at Novartis, including Head of Human Resources for Emerging Growth Markets; Head of Human Resources, United States and Canada, for Novartis Pharmaceuticals Corporation; and Global Head of Human Resources for Novartis Oncology. Prior to joining Novartis, he held HR positions at Bristol-Myers Squibb Co. and Unilever. Mr. Baert studied in Belgium and received a Master of Business Administration from Vlerick Business School in Ghent, a Master of Laws from the Katholieke Universiteit Leuven, and a Bachelor of Laws from the Katholieke Universiteit Brussels. He serves on the board of WeSeeHope USA, and from 2015 to 2018, he represented Novartis on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd.

Steffen Lang

Mr. Steffen Lang, Ph.D., has been Global Head of Novartis Technical Operations, Member of the Executive Committee of Novartis Inc. since April 1, 2018. He has been Global Head of Novartis Technical Operations since April 2017. Prior to his current appointment, Mr. Lang served as Global Head of Biologics Technical Development and Manufacturing within Novartis Technical Operations. He joined Novartis in 1994 as Head of Laboratory in Research, and over the years has held positions of increasing responsibility within Pharmaceuticals Development, including Head of Biotechnology Development and Global Head of Technical Research and Development. Mr. Lang holds a doctorate in pharmaceutical technology from the Swiss Federal Institute of Technology (ETH Zurich) in Switzerland, and a master’s degree in pharmaceutical sciences from the University of Heidelberg in Germany.

Klaus Moosmayer

Dr. Klaus Moosmayer, Ph.D., has been Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee of Novartis Inc. since December 1, 2018. He previously was Chief Compliance Officer of Siemens AG, a position he held from 2014. During his 18-year career at Siemens, he also served as chief counsel compliance, compliance operating officer and corporate legal counsel. Before joining Siemens, he practiced law in Germany, specializing in white-collar crime, litigation and business law. Dr. Moosmayer received his doctor of jurisprudence from the University of Freiburg in Germany and is internationally recognized in the field of compliance. He is chair of the Anti-Corruption Task Force of the Business and Industry Advisory Committee at the Organization for Economic Co-operation and Development (OECD); co-founder and chair of the European Chief Compliance and Integrity Officers’ Forum; former co-chair of the B20 Integrity & Compliance Task Force under the G20 presidency of Argentina; and former chair of the task force under the G20 presidency of Germany. Dr. Moosmayer lectures on compliance at the University of St.Gallen in Switzerland.

Shannon Klinger

Ms. Shannon Thyme Klinger has been Group General Counsel, Member of the Executive Committee of Novartis Inc. since June 1, 2018. She was Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee at the Company from April 1, 2018. Before that, she was Chief Ethics and Compliance Officer and Global Head of Litigation. She joined Novartis in 2011 as General Counsel, North America, for Sandoz in the United States and later became the Global Head of Legal and General Counsel for Sandoz International GmbH. Prior to Novartis, Ms. Klinger worked in the United States as a partner at Mayer Brown LLP from 2010 to 2011, senior vice president and general counsel for Solvay Pharmaceuticals Inc. from 2008 to 2010, and vice president of marketing compliance and associate counsel for Barr Laboratories/Duramed Pharmaceuticals from 2005 to 2007. She was also a partner at Alston & Bird LLP, where she focused on litigation and antitrust, pharmaceutical legal and regulatory matters. Ms. Klinger holds a juris doctor with honors from the University of North Carolina at Chapel Hill and a bachelor’s degree in psychology from the University of Notre Dame (both in the United States). She is a member of the board of directors of the SIX Group.

Bertrand Bodson

Mr. Bertrand Bodson has been Chief Digital Officer, Member of the Executive Committee of Novartis Inc. since April 1, 2018. He has been Chief Digital Officer at the Company since January 1, 2018. From 2013 to 2017, Mr. Bodson served as Chief Digital and Marketing Officer of Sainsbury’s Argos. Prior to that, he was Executive Vice President of the global digital business at EMI Music from 2010 to 2013. He co-founded Bragster.com, a social networking and content sharing website, and has also held senior roles at Amazon. Mr. Bodson earned a Master of Business Administration from Harvard Business School in the United States, where he was a Baker Scholar, and a master’s degree in commercial engineering from the Solvay Business School (Belgium)/McGill University (Canada). He is a member of the board of directors of Electrocomponents PLC.

James Bradner

Dr. James (Jay) Bradner, M.D., has served as President of the Novartis Institutes for BioMedical Research (NIBR) and Member of the Executive Committee of Novartis Inc. since March 1, 2016. He joined Novartis in January 2016. Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States from 2005 through 2015. He is a co-founder of five biotechnology companies and has authored more than 180 scientific publications and 30 US patent applications. Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the United States. He completed his residency in medicine at Brigham and Women’s Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

Richard Francis

Mr. Richard D. Francis has served as Chief Executive Officer of Sandoz and Member of the Executive Committee at Novartis Inc. since May 1, 2014. Mr. Francis joined Novartis from Biogen Idec, where he held global and country leadership positions during his 13-year career with the company. Most recently, he was senior vice president of the company’s United States commercial organization. From 1998 to 2001, he was at Sanofi in the United Kingdom, and held various marketing roles across the company’s urology, analgesics and cardiovascular products. He also held sales and marketing positions at Lorex Synthelabo and Wyeth. Mr. Francis is a member of the board of directors of Mettler-Toledo International Inc., based in the United States. He received a Bachelor of Arts in economics from Manchester Metropolitan University.

Paul Hudson

Mr. Paul Hudson has served as Chief Executive Officer of Novartis Pharmaceuticals and Member of the Executive Committee of Novartis Inc. since July 1, 2016. Mr. Hudson joined Novartis from AstraZeneca PLC, where he most recently was president, AstraZeneca United States and executive vice president, North America. He also served as representative director and president of AstraZeneca K.K. in Japan; as president of AstraZeneca’s business in Spain; and as vice president and primary care director, United Kingdom. Before joining AstraZeneca in 2006, Mr. Hudson held roles of increasing responsibility at Schering-Plough, including leading biologics global marketing. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthelabo UK. Mr. Hudson holds a degree in economics from Manchester Metropolitan University (MMU) and a diploma in marketing from the Chartered Institute of Marketing, also in the UK. In 2018, he was awarded an honorary doctorate in business administration from MMU. He is a board member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and vice chair of the Innovation Board Sponsored Committee of EFPIA.

Susanne Schaffert

Dr. Susanne Schaffert, Ph.D., has been CEO Novartis Oncology, Member of the Executive Committee of Novartis Inc. since January 1, 2019. She was appointed Chairperson and President of Advanced Accelerator Applications when it was acquired by Novartis in January 2018, and will remain President until her successor is in place. She joined Novartis more than 20 years ago and served as Region Head, Novartis Oncology Europe, from 2012 to 2018. Prior to that, she was Head of Investor Relations for Novartis. She has also held other leadership positions during her career at Novartis, including Global Franchise Head for Immunology and Infectious Diseases, General Manager of Novartis Oncology in Northern and Central Europe, and General Manager of Novartis Oncology in Germany. Dr. Schaffert holds a doctorate in organic chemistry from the University of Erlangen in Germany. She is a member of the Board of Novartis AG Germany, and previously served on the board of GlaxoSmithKline Consumer Healthcare Holdings Ltd.

John Tsai

Dr. John Tsai, M.D., has been Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee at Novartis Inc. since May 1, 2018. Dr. Tsai joined Novartis from Amgen Inc., where he was chief medical officer and senior vice president of Global Medical, overseeing all clinical and medical functions across multiple sites worldwide. Before joining Amgen in 2017, he spent 11 years at Bristol-Myers Squibb Co. (BMS), most recently as global head of clinical development for marketed products. During his time at BMS, Dr. Tsai also served as a full development team lead in oncology, head of Worldwide Medical, chief medical officer for Europe, vice president of US Medical, and vice president of Cardiovascular Medical. Prior to BMS, he was a cardiovascular group leader at Pfizer Inc. He started his career as an electrical engineer at General Electric Co. Dr. Tsai holds a medical degree from the University of Louisville School of Medicine in the United States. He received a Bachelor of Science in electrical engineering from Washington University in St. Louis, also in the United States.

Robert Weltevreden

Mr. Robert Weltevreden has been Head of Novartis Business Services (NBS), Member of the Executive Committee of Novartis Inc. since June 1, 2018. Mr. Weltevreden previously worked at Syngenta AG as head of its business services organization. He joined Syngenta in 2003 and has held other leadership positions, including head of business process management; head of finance services; and Chief Financial Officer (CFO) of the Asia-Pacific region for Syngenta Crop Protection AG. Prior to Syngenta, Mr. Weltevreden worked at Newell Rubbermaid Inc. as vice president/controller of Rubbermaid Europe and as CFO of the Germany, Benelux and Scandinavia markets. He started his career as a corporate business analyst at Curver and later became CFO of the Iberia region. Mr. Weltevreden holds a master’s degree in international finance, economics and business administration from Erasmus University Rotterdam in the Netherlands. He also holds a Master of Business Administration in financial management from Vlerick Business School in Ghent, Belgium.

Charlotte Pamer-Wieser

Ms. Charlotte Pamer-Wieser, Ph.D., has served as Corporate Secretary at Novartis Inc. since September 2011. She started her professional career in 2004 as an associate at Walder Wyss Ltd. in Zurich, Switzerland. From 2007 to 2011, she worked as a senior associate at Baer & Karrer Ltd. in Zurich. Her areas of specialization include corporate law, mergers and acquisitions, company reorganizations, and banking and finance law. Ms. Pamer-Wieser holds a doctorate in law from the University of Basel in Switzerland, and a Master of Laws from the University of Chicago Law School in the United States. In 2002, she was admitted to the Basel bar, and from 2007 to 2010, she was a lecturer at the University of Basel. She has written a number of articles on corporate law and is a member of the Association Internationale des Jeunes Avocats.

Nancy Andrews

Dr. Nancy C. Andrews, M.D., Ph.D., has been Non-Executive Independent Director of Novartis Inc. since February 27, 2015. She is a Member of the Research & Development Committee and the Risk Committee. Dr. Andrews is dean emerita of the Duke University School of Medicine and vice chancellor emerita for academic affairs at Duke University in the United States. She served as dean and vice chancellor from 2007 to 2017. She is a professor of pediatrics, pharmacology and cancer biology at Duke, and was elected as a fellow of the American Association for the Advancement of Science and to membership in the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She is chair of the board of directors of the American Academy of Arts and Sciences and of the Burroughs Wellcome Fund, a member of the Massachusetts Institute of Technology (MIT) Corporation, and former president of the American Society for Clinical Investigation. Additionally, she serves on the council of the National Academy of Medicine and on the Scientific Management Review Board of the US National Institutes of Health. Dr. Andrews holds a doctorate in biology from MIT and a doctor of medicine from Harvard Medical School. She completed her residency and fellowship trainings in pediatrics and hematology/oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute, also in the US, and served as an attending physician at Boston Children’s Hospital. Prior to joining Duke, Dr. Andrews was director of the Harvard/MIT M.D.-Ph.D. Program, and dean of basic sciences and graduate studies as well as professor of pediatrics at Harvard Medical School. From 1993 to 2006, she was a biomedical research investigator at the Howard Hughes Medical Institute in the US. Her research expertise is in iron homeostasis and mouse models of human diseases.

Dimitri Azar

Dr. Dimitri Azar, M.D., has been Non-Executive Independent Director of Novartis Inc. since February 2012. He is Member of the Governance, Nomination and Corporate Responsibilities Committee and the Research & Development Committee. Dr. Azar is senior director of ophthalmological innovation at Verily Life Sciences. He has also served as dean of the University of Illinois at Chicago (UIC) College of Medicine in the United States since 2011, and as professor of ophthalmology, bioengineering and pharmacology at UIC since 2006. From 2006 to 2011, he was head of the Department of Ophthalmology and Visual Sciences at UIC. He is a member of the American Ophthalmological Society, former president of the Chicago Ophthalmological Society, and president-elect of the Chicago Medical Society. Additionally, he is on the board of the Tear Film and Ocular Surface Society, the board of Verb Surgical Inc., and the scientific board of Verily – all based in the United States. Dr. Azar began his career at the American University of Beirut Medical Center in Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School. His research on matrix metalloproteinases in corneal wound healing and angiogenesis has been funded by the US National Institutes of Health since 1993. Dr. Azar practiced at the Wilmer Eye Institute at the Johns Hopkins Hospital School of Medicine in the US, and then returned to the Massachusetts Eye and Ear Infirmary as director of cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003. Dr. Azar holds a master’s degree from Harvard and an Executive Master of Business Administration from the University of Chicago Booth School of Business.

Ton Buechner

Mr. Ton Buechner has been Non-Executive Independent Director of Novartis Inc. since February 24, 2016. He is Member of the Audit and Compliance Committee. Mr. Buechner most recently served as chairman and CEO of the executive board of Dutch multinational Akzo- Nobel from 2012 to 2017. Prior to joining AkzoNobel, he spent almost two decades at the Sulzer Corporation in Switzerland, where he was appointed divisional president in 2001 and served as president and CEO from 2007 to 2011. Mr. Buechner’s early career was spent in the oil and gas construction industry, and included roles at Allseas Engineering in the Netherlands and at Aker Kvaerner in Singapore. He is a member of the supervisory board of Voith GmbH in Germany. Mr. Buechner is an engineer by training. He received his master’s degree in civil engineering from Delft University of Technology in the Netherlands in 1988, specializing in offshore construction technology and coastal engineering. Mr. Buechner holds a Master of Business Administration from IMD business school in Lausanne, Switzerland.

Srikant Datar

Mr. Srikant M. Datar, Ph.D., has served as Non-Executive Independent Director of Novartis Inc. since 2003. He is Chairman of the Risk Committee, as well as Member of the Audit and Compliance Committee and the Compensation Committee. The Board of Directors has appointed him as Audit Committee Financial Expert. Since 1996, Mr. Datar has been the Arthur Lowes Dickinson professor of business administration at Harvard Business School in the United States. Additionally, since 2015, he has been faculty chair of the Harvard Innovation Lab and senior associate dean for university affairs at Harvard Business School. He is a member of the boards of directors of ICF International Inc., Stryker Corp. and T-Mobile US. He previously served on the boards of HCL Technologies Ltd. (2012 to 2014) and KPIT Cummins Infosystems Ltd (2007 to 2012), both based in India. Mr. Datar graduated in 1973 with distinction in mathematics and economics from the University of Bombay in India. He is a chartered accountant, and holds two master’s degrees and a doctorate from Stanford University. Mr. Datar has worked as an accountant and planner in industry, and as a professor at Carnegie Mellon University, Stanford University and Harvard University, all in the US. His research interests are in the areas of cost management, measurement of productivity, new product development, innovation, time-based competition, incentives and performance evaluation. He is the author of many scientific publications and has received several academic awards and honors. Mr. Datar has also advised and worked with numerous companies in research, development and training.

Elizabeth Doherty

Ms. Elizabeth (Liz) Doherty has been Non-Executive Independent Director of Novartis Inc. since February 24, 2016. She is Chairman of the Audit and Compliance Committee and Member of the Risk Committee. The Board of Directors has appointed her as Audit Committee Financial Expert. Ms. Doherty is a senior independent director and chairman of the audit and risk committee of Dunelm Group PLC in the United Kingdom, and a member of the supervisory board and audit committee of Corbion NV in the Netherlands. She is a fellow of the Chartered Institute of Management Accountants; a non-executive board member of the UK Ministry of Justice; a non-executive board member of Her Majesty’s Courts and Tribunals Service in the UK; and an advisor to GBfoods and Affinity Petcare SA, subsidiaries of Agrolimen SA. She previously served as a non-executive director and audit committee member at Delhaize Group in Belgium and Nokia Corp. in Finland, and as a non-executive director at SABMiller PLC in the UK. Ms. Doherty received her bachelor’s degree in liberal studies in science (physics) from the University of Manchester in the UK. She began her career as an auditor and has held senior finance and accounting roles at Unilever PLC and Tesco PLC. Her previous positions also include interim chief financial officer (CFO) of Cognita Schools Ltd. from 2014 to 2015, CFO and board member of Reckitt Benckiser Group PLC from 2011 to 2013, interim CFO of City Inn in 2010, and CFO of Brambles Ltd. from 2007 to 2009.

Ann Fudge

Ms. Ann Marie Fudge has been Non-Executive Independent Director at Novartis Inc. since February 26, 2008. She is Member of the Compensation Committee; the Governance, Nomination and Corporate Responsibilities Committee; and the Risk Committee. Ms. Fudge is chair of the United States Program Advisory Panel of the Bill & Melinda Gates Foundation, and vice chairman of Boston-based WGBH Public Media. She is also a non-executive director of Northrop Grumman Corporation in the US, and a member of the visiting committee of Harvard Business School in the US. She served as a non-executive director of Unilever, London and Rotterdam, from 2009 to 2018, and as vice chairman and senior independent director of Unilever from 2015 to 2018. Additionally, she was a board member of General Electric Co. in the US from 1999 to 2015. Ms. Fudge received her bachelor’s degree from Simmons College and her Master of Business Administration from Harvard Business School. She is former chairman and CEO of Young & Rubicam Brands, New York. Before that, she served as president of the Beverages, Desserts and Post Division of Kraft Foods Inc.

Charles Sawyers

Dr. Charles L. Sawyers, M.D., has been Non-Executive Independent Director of Novartis Inc. since 2013. He is Member of the Research & Development Committee and the Governance, Nomination and Corporate Responsibilities Committee. In the United States, Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, professor of medicine and of cell and developmental biology at the Weill Cornell Graduate School of Medical Sciences, and an investigator at the Howard Hughes Medical Institute. He was appointed to the US National Cancer Advisory Board, and is former president of the American Association for Cancer Research and of the American Society for Clinical Investigation. He is also a member of the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He serves as a science advisor for the following companies: Agios Pharmaceuticals Inc., Housey Pharmaceutical Research Laboratories, Nextech Invest Ltd., Blueprint Medicines Corporation, Bei- Gene Ltd., The Column Group, ORIC Pharmaceuticals Inc., KSQ Therapeutics Inc., Foghorn Therapeutics Inc. and PMV Pharmaceuticals Inc. Dr. Sawyers received his doctor of medicine from the Johns Hopkins University School of Medicine, and worked at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, for nearly 18 years before joining Memorial Sloan Kettering in 2006. An internationally acclaimed cancer researcher, he co-developed the Novartis cancer drug Gleevec/Glivec and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award in 2009.

Frans van Houten

Mr. Frans van Houten has been Non-Executive Independent Director at Novartis Inc. since February 28, 2017. He is Member of the Research & Development Committee. Mr. van Houten is CEO and chairman of the executive committee and the board of management of Royal Philips, a position he has held since 2011. Under his leadership, Philips has transformed itself into a focused health technology company. From May 2016 through December 2017, he also served as vice chairman and a member of the supervisory board of Philips Lighting. Mr. van Houten holds a master’s degree in economics and business management from Erasmus University Rotterdam in the Netherlands. He joined Philips in 1986 and has held multiple global senior leadership positions. In 2009 and 2010, he was a consultant to the boards of companies such as ING Group NV and ASM International NV. Before that, he was CEO of NXP Semiconductors (a Philips spin-off) from 2004 to 2009.

Andreas von Planta

Mr. Andreas von Planta, Ph.D., has been Non-Executive Independent Director at Novartis Inc. since February 28, 2006. He is Chairman of the Governance, Nomination and Corporate Responsibilities Committee. He is also Member of the Risk Committee and the Audit and Compliance Committee. Mr. von Planta provides senior counsel to the law firm Lenz & Staehelin AG, where he was a partner from 1988 through 2017. He is chairman of HSBC Private Bank (Suisse) SA, chairman of the regulatory board of the SIX Swiss Exchange AG, and a board member of Helvetia Holding AG in Switzerland. He also serves on the boards of various Swiss subsidiaries of foreign companies and other non-listed Swiss companies, including Burberry (Suisse) SA, A.P. Moller Finance SA and Socotab Frana SA. He previously served on the boards of Raymond Weil SA (2007 to 2018) and Lenz & Staehelin (1996 to 2018), both based in Switzerland. Mr. von Planta holds a doctorate in law from the University of Basel in Switzerland, and a Master of Laws from Columbia Law School in the United States. He passed his bar examinations in Basel in 1982, and specializes in corporate law, corporate governance, corporate finance, company reorganizations, and mergers and acquisitions. He served as chairman of Clinique Generale-Beaulieu SA from 2011 to 2016, and as a director there from 2008 to 2016. Additionally, he was chairman of Swiss National Insurance Company Ltd. (Nationale Suisse) from 2011 to 2015, a director at Nationale Suisse from 1997 to 2015, and a director at Holcim Ltd. from 2003 to 2014.

William Winters

Mr. William Thomas (Bill) Winters, CBE, has been Non-Executive Independent Director of Novartis Inc. since 2013. He is Member of the Compensation Committee. Mr. Winters is CEO and a board member of Standard Chartered, based in London. He also serves on the board of Colgate University in the United States, and on the boards of the International Rescue Committee and the Print Room theater in the United Kingdom. Mr. Winters received his bachelor’s degree from Colgate University and his Master of Business Administration from the Wharton School of the University of Pennsylvania. From 2011 to 2015, he was chairman and CEO of Renshaw Bay, an alternative asset management firm. Prior to that, he was co-CEO of JPMorgan’s investment bank from 2003 to 2010. He joined JPMorgan in 1983 and has held management roles across several market areas and in corporate finance. Additionally, he was a commissioner on the UK Independent Commission on Banking in 2010 and 2011, and was awarded the title of Commander of the Order of the British Empire in 2013.

Samir Shah